Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 16/20 | 0.70 |
| ▸ | CLK3 | P49761 | 15/20 | 0.70 |
| ▸ | DYRK1A | Q13627 | 15/20 | 0.70 |
| ▸ | WNT1 | P04628 | 5/20 | 0.61 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20452525 | 0.97 | CLK2 (0.71) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL20452537 | 0.97 | CLK2 (0.73) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL20452515 | 0.97 | CLK2 (0.71) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL18442924 | 0.93 | CLK2 (0.81) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL20452691 | 0.91 | CLK2 (0.75) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL20452825 | 0.91 | CLK2 (0.68) | CLK2CLK3DYRK1AWNT1 | |
| SCHEMBL20964849 | 0.91 | CLK2 (0.81) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL18478874 | 0.91 | CLK2 (0.75) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL18494190 | 0.90 | CLK2 (0.79) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL18494187 | 0.90 | CLK2 (0.79) | CLK2CLK3DYRK1AWNT1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180221351-A1 | 3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2018-08-09 | — | — | US | claimed |
| US-10383861-B2 | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof | Sammumed, LLC (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180221351-A1 | 3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2018-08-09 | — | — | US | disclosed |
| US-20180221351-A1 | 3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2018-08-09 | — | — | US | disclosed |
| US-20160068563-A1 | 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10383861-B2 | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof | WNT3, WNT1, WNT3A | CLK2 2035/4885CLK3 1972/4885DYRK1A 806/4885 |
| US-20160068563-A1 | 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF | NR3C2, HSD3B1, HSD3B2 | CLK2 4619/4885CLK3 4757/4885DYRK1A 4761/4885 |
| US-20180221351-A1 | 3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF | WNT3, WNT1, WNT3A | CLK2 2035/4885CLK3 1972/4885DYRK1A 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.